Cross Analysis of End User W.R.T. Technology (USD Million), 2024-2037
Cross Analysis of End User W.R.T. Technology (USD Million), 2024-2037
Cross Analysis of End User W.R.T. Technology (USD Million), 2024-2037
Cross Analysis of End User W.R.T. Technology (USD Million), 2024-2037
Cross Analysis of End User W.R.T. Technology (USD Million), 2024-2037
Cross Analysis of End user W.R.T. Technology (USD Million), 2024-2037
Cross Analysis of End User W.R.T. Technology (USD Million), 2024-2037
Non Invasive Prenatal Testing Market size is assessed at USD 4.5 billion in 2024 and is projected to exceed USD 14.5 billion by the end of 2037, expanding at over 9.4% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of non-invasive prenatal testing (NIPT) is evaluated at USD 4.9 billion.
This non invasive prenatal testing (NIPT) market growth can be attributed to the rise in maternal age, an increase in awareness of genetic disorders, and technological advancements in genomic sequencing. Individuals are looking forward to safer, accurate ways due to which NIPT emerged as a favored choice over the earlier risky invasive detection techniques. Major companies in the NIPT sector are displaying active investments in research and development activities for further improvement in their test capacities and geographic expansion.
One of the most recent advances taken place in the industry is from Invitae Corporation, an announcement in March 2024 stating that its new platform for NIPT, developed to present exhaustive coverage of rare genetic conditions, is expected to have greater accuracy for detecting common trisomy. This is another notable factor that companies are working to be competitive to continue to change to meet the needs of health providers, together with their patients.
The government and other regulatory bodies are also playing their role in boosting the NIPT market growth. There have been updates in the prenatal screening guidelines by many countries. This first-line option of screening is essential for envisaging high-risk pregnancies. For example, the UK National Health Service has been gradually introducing NIPT into its prenatal screening program. This is probably driven by growing attitudes toward NIPT; as per statistics from NHS, in 2023, around 65% of the eligible pregnant population in England had undergone NIPT testing. Moreover, increasing government initiatives to raise awareness about genetic disorders and improvement in access to prenatal care are further expected to drive the non invasive prenatal testing market in the upcoming years.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
9.4% |
|
Base Year Market Size (2024) |
USD 4.5 Billion |
|
Forecast Year Market Size (2037) |
USD 14.5 Billion |
|
Regional Scope |
|
Gestational Age (0-12 weeks, 13-24 weeks, 25–36 weeks)
13-24 weeks segment is poised to account for non invasive prenatal testing market share of more than 51.4% by the end of 2037. It is anticipated to continue dominating other segments with a strong CAGR of 9.5% from 2025 to 2037. The segment is leading as detection in the second trimester provides an optimal window between detection and test accuracy. This timeframe is also easily combined with other crucial prenatal screening tests, such as ultrasound and serum screening for alpha-fetoprotein.
A recent development related to this was by Illumina, Inc. in January 2024 when they launched VeriSeq NIPT Solution v2. This new solution enables the test to detect partial deletions and duplications of all chromosomes with the test, greatly enhancing its power to recognize a wider range of genetic anomalies during these critical weeks from 13-24.
Method (Biochemical screening tests, Maternal cell-free DNA, Plasma testing, Ultrasonic Detection)
The maternal cell-free DNA segment in non invasive prenatal testing market dominated the revenue in 2024 and is projected to continue with a 9.6% CAGR from 2025 to 2037. The growth of the segment is propelled by technological advancements that extend the testing capabilities to whole genome sequencing for the detection of microdeletions and sex chromosomal abnormalities. Increasing product launches and improving reimbursement scenarios also contribute to NIPT market growth and both, directly and indirectly make these tests accessible to a larger population.
As per a report from the National Institutes of Health in August 2023, the adoption rate for cfDNA-based NIPT is over 75% among pregnant women in high-income countries. This represents an increase of 15% from that reported in 2022 and outlines the acceptance and integration of NIPT into standard prenatal care protocols. To tap into the opportunity, companies are launching various innovative tests.
For example, in March 2024, Roche announced the launch of its HARMONY prenatal test with expanded capabilities. Innovations like these from companies enable extra rare chromosomal conditions, allowing more inclusively rounded insight into fetal health during pregnancy.
Our in-depth analysis of the global non invasive prenatal testing market includes the following segments:
|
Gestational Age |
|
|
Pregnancy Risk |
|
|
Method |
|
|
Technology |
|
|
Product |
|
|
Application |
|
|
End user |
|
APEJ Market Statistics
Asia Pacific Excluding Japan non invasive prenatal testing market size is poised to exceed USD 3.042 billion by 2037, representing a CAGR of 9.8% from 2025 to 2037. This expansion is driven by the increasing maternal age across the region, leading to a higher incidence of chromosomal aneuploidies in infants.
Furthermore, improved and developed healthcare infrastructure also acts as a driver to access such advanced prenatal screening techniques for Asia Pacific. A key development that supports this trend is the increasing collaboration among regional and global players in the NIPT space. For instance, in October 2023, BGI Genomics partnered with one of the major healthcare providers in Singapore to establish a NIPT laboratory, further fanning growth demand in Southeast Asia.
China offers the highest market potential, driven by its large population and rapidly improving healthcare sector. The cultural emphasis on prenatal care, coupled with investment that it is funneling into biotechnology, creates fertile ground for the NIPT market to grow.
India’s non-invasive prenatal testing (NIPT) industry is driven by various social, economic, and technological factors. With the increase in DISC (Double Income, Single Child) families in urban areas, people have increased investments in prenatal care. This is likely to boost the adoption of advanced screening methods like NIPT, calling investments from companies.
For instance, in August 2022, Bengaluru-based genetic diagnostics company MedGenome raised USD 50 million for a minority stake led by Novo Holdings. This followed a round led by LeapFrog Investments and Sofina. Further, the market is being further witnessing a rise in adoption of vitro fertilization techniques, thereby fueling the demand for comprehensive prenatal testing.
North America Market Analysis
North America non invasive prenatal testing market is set to capture revenue share of around 37.3% by the end of 2036.The reasons behind this growth are superior, more developed healthcare infrastructure, better awareness about advanced techniques in medications, and good reimbursement policies.
North America’s non invasive prenatal testing market stood at a valuation of USD 1.6 billion in 2024 and is likely to cross USD 5.5 billion by 2037, rising at a CAGR of 9.5% from 2025 to 2037. Increasing maternal age, better acceptance of prenatal screening methods, and continuous technological innovations turn out to be the principal drivers of this market.
The United States non invasive prenatal testing market is anticipated to cross a valuation of 3.4 billion, expanding at a CAGR of 9.7% by 2037. Market growth is further fueled by guidelines from organizations such as the American College of Obstetricians and Gynecologists, which recommended NIPT for all pregnancies in 2023—expanding its base of users for NIPT services. Better insurance coverage also drives higher accessibility: the report indicates over 70% of private insurance plans now cover NIPT, up from 55% in 2021. There is an increase in competition and innovations in the market, with companies designing AI-driven NIPT platforms in 2024 that give higher accuracy and faster results.
The NIPT market in Canada is set to register a revenue CAGR of 9.3% during the forecast period, driven by integration within provincial healthcare systems. The market also trends toward localized testing, reducing reliance on U.S. labs. To fill the demand gap, companies are expanding their roots to Canada via mergers and acquisitions.
For example, in July 2024, Quest Diagnostics announced a definitive agreement to acquire LifeLabs, a trusted provider of community laboratory tests for millions of Canadians. The acquisition is valued at approximately CAD 1.35 billion, including net debt. This development not only enhances accessibility to NIPT testing but also supports the development of local expertise and infrastructure for advanced prenatal diagnostics in Canada.
The competitive outlook for the NIPT market is marked by rapid innovation and strategic collaborations aimed at enhancing testing capabilities and market reach. Key players like Natera, Illumina, and Roche are leading the charge, developing advanced technologies that offer greater accuracy and a broader range of genetic screenings.
Companies are now working toward enhancing accessibility for the end user and integrating Non-Invasive Prenatal Testing (NIPT) into routine prenatal care as consumer demand for comprehensive prenatal testing increases in the competitive market. Here is a list of key players operating in the global market:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?